Impaired nitric oxide synthase-2 signaling pathway in cystic fibrosis airway epithelium

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 287, Issue 2 31-2, 2004, Pages

  Zheng, Shuo ^a   Xu, Weiling ^a   Bose, Santanu ^a   Banerjee, Amiya K ^a   Haque, S Jaharul ^a   Erzurum, Serpil C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antiviral host defense; IFN inducible factor; Signal transducer and activator of transcription 1

Indexed keywords

GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; STAT1 PROTEIN; TRANSCRIPTION FACTOR AP 1;

ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DELAYED RESPONSIVE GENE; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME MECHANISM; EPITHELIUM CELL; GENE; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSCRIPTION; HOST RESISTANCE; HUMAN; HUMAN CELL; INFECTION SENSITIVITY; MEDIATOR RELEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; VIRUS INFECTION;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ANTINEOPLASTIC AGENTS; CAENORHABDITIS ELEGANS PROTEINS; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; CYSTIC FIBROSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERFERON TYPE II; LUNG NEOPLASMS; PROMOTER REGIONS (GENETICS); RESPIRATORY MUCOSA; SIGNAL TRANSDUCTION;

EID: 3242702434     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00039.2004     Document Type: Article

References (44)

1. Asano K, Chee CB, Gaston B, Lilly CM, Gerard C, Drazen JM, and Stamler JS. Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc Natl Acad Sci USA 91: 10089-10093, 1994.
2. Balfour-Lynn IM, Laverty A, and Dinwiddie R. Reduced upper airway nitric oxide in cystic fibrosis. Arch Dis Child 75: 319-322, 1996.
3. Bals R, Weiner DJ, and Wilson JM. The innate immune system in cystic fibrosis lung disease. J Clin Invest 103: 303-307, 1999.
4. Belvisi M, Barnes PJ, Larkin S, Yacoub M, Tadjkarimi S, Williams TJ, and Mitchell JA. Nitric oxide synthase activity is elevated in inflammatory lung disease in humans. Eur J Pharmacol 283: 255-258, 1995.
5. Chu SC, Marks-Konczalik J, Wu HP, Banks TC, and Moss J. Analysis of the cytokine-stimulated human inducible nitric oxide synthase (iNOS) gene: characterization of differences between human and mouse iNOS promoters. Biochem Biophys Res Commun 248: 871-878, 1998.
6. Comhair SA, Thomassen MJ, and Erzurum SC. Differential induction of extracellular glutathione peroxidase and nitric oxide synthase 2 in airways of healthy individuals exposed to 100% 0(2) or cigarette smoke. Am J Respir Cell Mol Biol 23: 350-354, 2000.
7. Darnell JE Jr, Kerr IM, and Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421, 1994.
8. De BP, Gupta S, and Banerjee AK. Cellular protein kinase C isoform zeta regulates human parainfluenza virus type 3 replication. Proc Natl Acad Sci USA 92: 5204-5208, 1995.
9. De Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH, and Williams BR. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69: 912-920, 2001.
10. DeLong PA and Kotloff RM. An overview of pulmonary host defense. Semin Roentgenol 35: 118-123, 2000.
11. Dogusan Z, Hooghe R, Verdood P, and Hooghe-Peters EL. Cytokine-like effects of prolactin in human mononuclear and polymorphonuclear leukocytes. J Neuroimmunol 120: 58-66, 2001.
12. Elphick HE, Demoncheaux EA, Ritson S, Higenbottam TW, and Everard ML. Exhaled nitric oxide is reduced in infants with cystic fibrosis. Thorax 56: 151-152, 2001.
13. Enders JF, McCarthy CK, Mitus A, and Cheatham WJ. Isolation of measles virus at autopsy in cases of giant-cell pneumonia without rash. N Engl J Med 261: 875-881, 1959.
14. Ganz T. Antimicrobial polypeptides in host defense of the respiratory tract. J Clin Invest 109: 693-697, 2002.
15. Guo FH, De Raeve HR, Rice TW, Stuehr DJ, Thunnissen FB, and Erzurum SC. Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc Natl Acad Sci USA 92: 7809-7813, 1995.
16. Guo FH and Erzurum SC. Characterization of inducible nitric oxide synthase expression in human airway epithelium. Environ Health Perspect 106, Suppl 5: 1119-1124, 1998.
17. Guo FH, Uetani K, Haque SJ, Williams BR, Dweik RA, Thunnissen FB, Calhoun W, and Erzurum SC. Interferon gamma and interleukin 4 stimulate prolonged expression of inducible nitric oxide synthase in human airway epithelium through synthesis of soluble mediators. J Clin Invest 100: 829-838, 1997.
18. Hamid Q, Springall DR, Riveros-Moreno V, Chanez P, Howarth P, Redington A, Bousquet J, Godard P, Holgate S, and Polak JM. Induction of nitric oxide synthase in asthma. Lancet 342: 1510-1513, 1993.
19. Haque SJ and Williams BR. Signal transduction in the interferon system. Semin Oncol 25: 14-22, 1998.
20. Hartshorn KL, Holmskov U, Hansen S, Zhang P, Meschi J, Mogues T, White MR, and Crouch EC. Distinctive anti-influenza properties of recombinant collectin 43. Biochem J 366: 87-96, 2002.
21. Hill CS and Treisman R. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell 80: 199-211, 1995.
22. Huang NN, Macri CN, Girone J, and Sproul A. Survival of patients with cystic fibrosis. Am J Dis Child 120: 289-295, 1970.
23. Kelley TJ and Drumm ML. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 102: 1200-1207, 1998.
24. Kelley TJ and Elmer HL. In vivo alterations of IFN regulatory factor-1 and PIAS1 protein levels in cystic fibrosis epithelium. J Clin Invest 106: 403-410, 2000.
25. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, and Barnes PJ. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 343: 133-135, 1994.
26. Kobzik L, Bredt DS, Lowenstein CJ, Drazen J, Gaston B, Sugarbaker D, and Stamler JS. Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. Am J Respir Cell Mol Biol 9: 371-377, 1993.
27. Konno S, Grindle KA, Lee WM, Schroth MK, Mosser AG, Brockman-Schneider RA, Busse WW, and Gern JE. Interferon-gamma enhances rhinovirus-induced RANTES secretion by airway epithelial cells. Am J Respir Cell Mol Biol 26: 594-601, 2002.
28. Konstan MW and Melvin B. Infection and inflammation of the lung in cystic fibrosis. In: Cystic Fibrosis, edited by Davis PB. New York: Dekker, 1993, vol. 64, p. 223-233. (Lung Biol. Health Dis. Ser.)
29. Kreiselmeier NE, Kraynack NC, Corey DA, and Kelley TJ. Statin-mediated correction of STAT1 signaling and inducible nitric oxide synthase expression in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol Physiol 285: L1286-L1295, 2003.
30. Lundberg JO, Nordvall SL, Weitzberg E, Kollberg H, and Alving K. Exhaled nitric oxide in paediatric asthma and cystic fibrosis. Arch Dis Child 75: 323-326, 1996.
31. Marks-Konczalik J, Chu SC, and Moss J. Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor kappaB-binding sites. J Biol Chem 273: 22201-22208, 1998.
32. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179-185, 1995.
33. Meng QH, Springall DR, Bishop AE, Morgan K, Evans TJ, Habib S, Gruenert DC, Gyi KM, Hodson ME, Yacoub MH, and Polak JM. Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. J Pathol 184: 323-331, 1998.
34. Sanders SP, Siekierski ES, Porter JD, Richards SM, and Proud D. Nitric oxide inhibits rhinovirus-induced cytokine production and viral replication in a human respiratory epithelial cell line. J Virol 72: 934-942, 1998.
35. Saura M, Zaragoza C, Bao C, McMillan A, and Lowenstein CJ. Interaction of interferon regulatory factor-1 and nuclear factor kappaB during activation of inducible nitric oxide synthase transcription. J Mol Biol 289: 459-471, 1999.
36. Sekaly RP, Tonnelle C, Strubin M, Mach B, and Long EO. Cell surface expression of class II histocompatibility antigens occurs in the absence of the invariant chain. J Exp Med 164: 1490-1504, 1986.
37. Shwachman H, Katz S, and Kulczycki LL. Attenuated measles vaccine in cystic fibrosis. Am J Dis Child 103: 405-409, 1962.
38. Stark GR, Kerr IM, Williams BR, Silverman RH, and Schreiber RD. How cells respond to interferons. Annu Rev Biochem 67: 227-264, 1998.
39. Uetani K, Thomassen MJ, and Erzurum SC. Nitric oxide synthase 2 through an autocrine loop via respiratory epithelial cell-derived mediator. Am J Physiol Lung Cell Mol Physiol 280:L1179-L1188, 2001.
40. Vera-Lastra O, Jara LJ, and Espinoza LR. Prolactin and autoimmunity. Autoimmun Rev 1: 360-364, 2002.
41. Warner RL, Paine R III, Christensen PJ, Marletta MA, Richards MK, Wilcoxen SE, and Ward PA. Lung sources and cytokine requirements for in vivo expression of inducible nitric oxide synthase. Am J Respir Cell Mol Biol 12: 649-661, 1995.
42. Williams BR. Transcriptional regulation of interferon-stimulated genes. Eur J Biochem 200: 1-11, 1991.
43. Xu W, Comhair SA, Zheng S, Chu SC, Marks-Konczalik J, Moss J, Haque SJ, and Erzurum SC. STAT-1 and c-Fos interaction in nitric oxide synthase-2 gene activation. Am J Physiol Lung Cell Mol Physiol 285: L137-L148, 2003.
44. Zheng S, De BP, Choudhary S, Comhair SA, Goggans T, Slee R, Williams BR, Pilewski J, Haque SJ, and Erzurum SC. Impaired innate host defense causes susceptibility to respiratory virus infections in cystic fibrosis. Immunity 18: 619-630, 2003.